Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Pancreatic Neoplasms 685Carcinoma, Non-Small-Cell Lung 328Neoplasms 170Breast Neoplasms 166Lung Neoplasms 158Urinary Bladder Neoplasms 157Neoplasm Metastasis 140Cholangiocarcinoma 113Ovarian Neoplasms 106Biliary Tract Neoplasms 95Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 71Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 61Carcinoma, Transitional Cell 56Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Lymphoma, Non-Hodgkin 48Fallopian Tube Neoplasms 48Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

Pemetrexed 2Gemcitabine 2Cisplatin 2Carboplatin 2CP protocol 2durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non Small Cell Lung Carcinoma NSCLC × Gemcitabine × Clear all
NCT02542293 2026-05-01

NEPTUNE

AstraZeneca

Phase 3 Active not recruiting
953 enrolled 29 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡